Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

This study tests a drug called talazoparib combined with targeted radiation therapy in women whose gynecologic cancers (ovarian, cervical, endometrial, vaginal, fallopian tube, or peritoneal) have come back in the belly or pelvis after prior treatment. **You may be eligible if...** - You have a confirmed recurrence of ovarian, fallopian tube, peritoneal, endometrial, vaginal, or cervical cancer in the abdomen or pelvis - Your hemoglobin (red blood cell level) is at least 10.0 g/dL without a recent transfusion - If you have spread to other areas, that disease must be stable for at least 3 months and not need immediate chemotherapy - You are willing to stop certain other cancer therapies at least 3 weeks before starting this study **You may NOT be eligible if...** - Your blood counts or organ function are too low - You are pregnant or breastfeeding - You have recently had a blood transfusion Talk to your doctor to see if this trial is right for you.